JP2016525560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525560A5 JP2016525560A5 JP2016530509A JP2016530509A JP2016525560A5 JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5 JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016530509 A JP2016530509 A JP 2016530509A JP 2016525560 A5 JP2016525560 A5 JP 2016525560A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- seq
- use according
- sequence
- cell binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306119.2 | 2013-08-02 | ||
| EP13306119 | 2013-08-02 | ||
| PCT/EP2014/066345 WO2015014879A1 (en) | 2013-08-02 | 2014-07-30 | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525560A JP2016525560A (ja) | 2016-08-25 |
| JP2016525560A5 true JP2016525560A5 (enExample) | 2017-07-13 |
Family
ID=49036539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016530509A Abandoned JP2016525560A (ja) | 2013-08-02 | 2014-07-30 | 固形腫瘍を処置するための抗−Ｍｕｃ１メイタンシノイドイムノコンジュゲート抗体の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347856A1 (enExample) |
| EP (1) | EP3027218A1 (enExample) |
| JP (1) | JP2016525560A (enExample) |
| KR (1) | KR20160035600A (enExample) |
| CN (1) | CN105592861A (enExample) |
| AU (1) | AU2014298514A1 (enExample) |
| CA (1) | CA2919932A1 (enExample) |
| EA (1) | EA201690321A1 (enExample) |
| IL (1) | IL243843A0 (enExample) |
| MX (1) | MX2016001541A (enExample) |
| TW (1) | TW201605479A (enExample) |
| WO (1) | WO2015014879A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701328XA (en) * | 2014-09-02 | 2017-03-30 | Immunogen Inc | Methods for formulating antibody drug conjugate compositions |
| GB201506388D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W | Site-specific antibody-drug conjugates |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| CN105997942B (zh) * | 2016-06-24 | 2019-01-29 | 浙江大学 | 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用 |
| EP3570881A4 (en) * | 2017-01-18 | 2020-08-19 | Nanocruise Pharmaceutical Ltd. | MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE |
| CA3072399A1 (en) * | 2017-08-09 | 2019-02-14 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| US20220023439A1 (en) * | 2018-11-02 | 2022-01-27 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1291898A (zh) * | 1998-02-25 | 2001-04-18 | 若素制药株式会社 | 用于角膜上皮疾病的药物 |
| ATE496944T1 (de) * | 2003-07-21 | 2011-02-15 | Immunogen Inc | Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung |
| CA2615761A1 (en) * | 2005-08-22 | 2007-03-01 | Immunogen, Inc. | Humanized anti-ca6 antibodies and methods of using the same |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| CN102596922A (zh) * | 2009-10-06 | 2012-07-18 | 免疫基因公司 | 有效的缀合物和亲水性连接体 |
-
2014
- 2014-07-30 AU AU2014298514A patent/AU2014298514A1/en not_active Withdrawn
- 2014-07-30 WO PCT/EP2014/066345 patent/WO2015014879A1/en not_active Ceased
- 2014-07-30 CN CN201480054398.5A patent/CN105592861A/zh active Pending
- 2014-07-30 EA EA201690321A patent/EA201690321A1/ru unknown
- 2014-07-30 JP JP2016530509A patent/JP2016525560A/ja not_active Abandoned
- 2014-07-30 US US14/909,671 patent/US20160347856A1/en not_active Abandoned
- 2014-07-30 MX MX2016001541A patent/MX2016001541A/es unknown
- 2014-07-30 CA CA2919932A patent/CA2919932A1/en not_active Withdrawn
- 2014-07-30 EP EP14747592.5A patent/EP3027218A1/en active Pending
- 2014-07-30 KR KR1020167004778A patent/KR20160035600A/ko not_active Withdrawn
- 2014-08-01 TW TW103126492A patent/TW201605479A/zh unknown
-
2016
- 2016-01-31 IL IL243843A patent/IL243843A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525560A5 (enExample) | ||
| JP7425026B2 (ja) | フタロシアニン色素コンジュゲートおよびその保存法 | |
| CN111587124B (zh) | Ror1抗体免疫缀合物 | |
| JP2024522312A (ja) | 抗体薬物複合体の調製方法および使用 | |
| JP7585230B2 (ja) | バイパラトピックＦＲ－α抗体及びイムノコンジュゲート | |
| ES2992591T3 (en) | Compositions, combinations and related methods for photoimmunotherapy | |
| CN106999604B (zh) | 用于配制抗体药物缀合物组合物的方法 | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2014515036A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2017535246A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
| HRP20240917T1 (hr) | Režimi doziranja anti-folr1 imunokonjugata | |
| JP2016538318A5 (enExample) | ||
| CN112512583B (zh) | 酞菁染料偶联物组合物 | |
| CA2858133A1 (en) | Uses of immunoconjugates targeting cd138 | |
| Lidický et al. | Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab | |
| TW201919711A (zh) | 預防免疫結合物中之甲硫胺酸氧化之方法 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 | |
| WO2024213081A1 (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| CN121240889A (zh) | 抗体药物缀合物 | |
| HK40048277A (en) | Phthalocyanine dye conjugates and their storage | |
| BR112019027448B1 (pt) | Imunoconjugado compreendendo um anticorpo conjugado a uma porção de fármaco citotóxica, composição farmacêutica e uso dos mesmos |